Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 0.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 32.2; sample size: 30.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 37.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 22.0; sample size: 50.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 37.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 32.0; sample size: 30.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 29.5; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 27.0; sample size: 40.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 22.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 22.0; sample size: 50.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 36.8; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 74.2; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.3/100. Study design: 45.0; human relevance: 85.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 36.2; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 36.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 61.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 36.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
